Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
Alpha Teknova (Nasdaq: TKNO), a producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has announced it will release its third quarter 2024 financial results on November 7, 2024, after market close. The company will host a webcast and conference call at 5:30 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website section, and participants need to register to receive dial-in information.
Alpha Teknova (Nasdaq: TKNO), produttore di reagenti critici per lo sviluppo di terapie, vaccini e diagnosi molecolari, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 il 7 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà un webcast e una conferenza telefonica alle 17:30, ora orientale, nello stesso giorno. Gli investitori possono accedere al webcast attraverso la sezione Relazioni con gli Investitori del sito di Teknova, e i partecipanti devono registrarsi per ricevere le informazioni di accesso.
Alpha Teknova (Nasdaq: TKNO), productor de reactivos críticos para el desarrollo de terapias, vacunas y diagnósticos moleculares, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el 7 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo un webcast y una conferencia telefónica a las 5:30 p.m., hora del Este, el mismo día. Los inversores pueden acceder al webcast a través de la sección de Relaciones con Inversores del sitio web de Teknova, y los participantes deben registrarse para recibir la información de acceso.
알파 테크노바 (Nasdaq: TKNO)는 치료제, 백신 및 분자 진단 개발을 위한 중요한 시약을 생산하는 회사로, 2024년 3분기 재무 결과를 2024년 11월 7일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시로 오후 5시 30분에 웹캐스트 및 컨퍼런스 콜을 진행할 예정입니다. 투자자는 Teknova의 투자자 관계 웹사이트 섹션을 통해 웹캐스트에 액세스할 수 있으며, 참가자는 전화 접속 정보를 받기 위해 등록해야 합니다.
Alpha Teknova (Nasdaq: TKNO), producteur de réactifs critiques pour le développement de thérapies, de vaccins et de diagnostics moléculaires, a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le 7 novembre 2024, après la clôture des marchés. L'entreprise organisera un webcast et une conférence téléphonique à 17h30, heure de l'Est, le même jour. Les investisseurs peuvent accéder au webcast via la section Relations avec les investisseurs du site web de Teknova, et les participants doivent s'inscrire pour recevoir les informations de connexion.
Alpha Teknova (Nasdaq: TKNO), ein Hersteller von kritischen Reagenzien für die Entwicklung von Therapien, Impfstoffen und molekularen Diagnosen, hat angekündigt, dass es am 7. November 2024 nach Börsenschluss seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 17:30 Uhr Eastern Time ein Webcast und eine Telefonkonferenz veranstalten. Anleger können über den Bereich Investor Relations auf der Website von Teknova auf den Webcast zugreifen, und Teilnehmer müssen sich registrieren, um die Einwahlinformationen zu erhalten.
- None.
- None.
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.
Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. The Company’s fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps their customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by its team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
This press release was published by a CLEAR® Verified individual.
FAQ
When will Teknova (TKNO) report Q3 2024 earnings?
What time is Teknova's (TKNO) Q3 2024 earnings call?
How can I access Teknova's (TKNO) Q3 2024 earnings call?
